Who
Roy A. Whitfield
Director
Company insider
Files Form 4 as: Director, Nektar Therapeutics; Director, Illumina; Director, Incyte; Director, Solexa.
In numbers
- Trades disclosed
- 337
- Buys
- 3
- Sells
- 48
- Bought
- $918K
- Sold
- $22.5M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 22 Dec 2005
- Last trade
- 23 Sep 2026
- Last filed
- 25 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
| 30 Sep 2025filed 1 Oct 2025 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 18 Sep 2024filed 17 Jan 2025 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 19 Sep 2023filed 20 Sep 2023 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —85,000 at $0.00 | filing |
| 14 Jun 2023filed 15 Jun 2023 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $17K30,000 at $0.57 | filing |
| 16 Sep 2022filed 20 Sep 2022 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 16 Sep 2022filed 20 Sep 2022 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,200 at $0.00 | filing |
| 22 Sep 2021filed 24 Sep 2021 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 22 Sep 2021filed 24 Sep 2021 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,200 at $0.00 | filing |
| 16 Sep 2021filed 17 Sep 2021 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
| 16 Sep 2021filed 17 Sep 2021 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code M | $552K40,000 at $13.80 | filing |
| 30 Dec 2020filed 4 Jan 2021 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code G | —51,500 at $0.00 | filing |
| 30 Dec 2020filed 4 Jan 2021 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code G | —51,500 at $0.00 | filing |
| 22 Sep 2020filed 25 Sep 2020 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,200 at $0.00 | filing |
| 22 Sep 2020filed 25 Sep 2020 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —9,100 at $0.00 | filing |
| 22 Sep 2020filed 24 Sep 2020 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,200 at $0.00 | filing |
| 22 Sep 2020filed 24 Sep 2020 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —9,100 at $0.00 | filing |
News
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY)INCY · themarketsdaily.com · 20 Oct 2026Illumina To Webcast Upcoming Investor ConferenceILMN · prnewswire.com · 20 Oct 2026Nektar Therapeutics (NASDAQ:NKTR) Research Coverage Started at Leerink PartnersNKTR · tickerreport.com · 15 Oct 2026Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at Leerink PartnersNKTR · themarketsdaily.com · 13 Oct 2026Illumina's (ILMN) Sequencing Business Is Recovering, But Is the Stock Getting Ahead of Itself?ILMN · insidermonkey.com · 13 Oct 2026
0 headlines in the last 90 days name Roy A. Whitfield; 5 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.